Browse by author
Lookup NU author(s): Professor Nicola CurtinORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020, Springer Nature Limited. The process of poly(ADP-ribosyl)ation and the major enzyme that catalyses this reaction, poly(ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since then, advances in our understanding of the roles of PARP1 in cellular processes such as DNA repair, gene transcription and cell death have allowed the investigation of therapeutic PARP inhibition for a variety of diseases — particularly cancers in which defects in DNA repair pathways make tumour cells highly sensitive to the inhibition of PARP activity. Efforts to identify and evaluate potent PARP inhibitors have so far led to the regulatory approval of four PARP inhibitors for the treatment of several types of cancer, and PARP inhibitors have also shown therapeutic potential in treating non-oncological diseases. This Review provides a timeline of PARP biology and medicinal chemistry, summarizes the pathophysiological processes in which PARP plays a role and highlights key opportunities and challenges in the field, such as counteracting PARP inhibitor resistance during cancer therapy and repurposing PARP inhibitors for the treatment of non-oncological diseases.
Author(s): Curtin NJ, Szabo C
Publication type: Review
Publication status: Published
Journal: Nature Reviews Drug Discovery
Year: 2020
Volume: 19
Issue: 10
Pages: 711-736
Print publication date: 01/10/2020
Online publication date: 03/09/2020
Acceptance date: 30/06/2020
ISSN (print): 1474-1776
ISSN (electronic): 1474-1784
Publisher: Nature Research
URL: https://doi.org/10.1038/s41573-020-0076-6
DOI: 10.1038/s41573-020-0076-6
PubMed id: 32884152
